Literature DB >> 20461783

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.

Frederick Wolfe1, Daniel J Clauw, Mary-Ann Fitzcharles, Don L Goldenberg, Robert S Katz, Philip Mease, Anthony S Russell, I Jon Russell, John B Winfield, Muhammad B Yunus.   

Abstract

OBJECTIVE: To develop simple, practical criteria for clinical diagnosis of fibromyalgia that are suitable for use in primary and specialty care and that do not require a tender point examination, and to provide a severity scale for characteristic fibromyalgia symptoms.
METHODS: We performed a multicenter study of 829 previously diagnosed fibromyalgia patients and controls using physician physical and interview examinations, including a widespread pain index (WPI), a measure of the number of painful body regions. Random forest and recursive partitioning analyses were used to guide the development of a case definition of fibromyalgia, to develop criteria, and to construct a symptom severity (SS) scale.
RESULTS: Approximately 25% of fibromyalgia patients did not satisfy the American College of Rheumatology (ACR) 1990 classification criteria at the time of the study. The most important diagnostic variables were WPI and categorical scales for cognitive symptoms, unrefreshed sleep, fatigue, and number of somatic symptoms. The categorical scales were summed to create an SS scale. We combined the SS scale and the WPI to recommend a new case definition of fibromyalgia: (WPI > or =7 AND SS > or =5) OR (WPI 3-6 AND SS > or =9).
CONCLUSION: This simple clinical case definition of fibromyalgia correctly classifies 88.1% of cases classified by the ACR classification criteria, and does not require a physical or tender point examination. The SS scale enables assessment of fibromyalgia symptom severity in persons with current or previous fibromyalgia, and in those to whom the criteria have not been applied. It will be especially useful in the longitudinal evaluation of patients with marked symptom variability.

Entities:  

Mesh:

Year:  2010        PMID: 20461783     DOI: 10.1002/acr.20140

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  914 in total

Review 1.  Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jost Langhorst; Petra Klose; Gustav J Dobos; Kathrin Bernardy; Winfried Häuser
Journal:  Rheumatol Int       Date:  2012-02-15       Impact factor: 2.631

2.  Executive function in chronic pain patients and healthy controls: different cortical activation during response inhibition in fibromyalgia.

Authors:  Jennifer M Glass; David A Williams; Maria-Luisa Fernandez-Sanchez; Anson Kairys; Paloma Barjola; Mary M Heitzeg; Daniel J Clauw; Tobias Schmidt-Wilcke
Journal:  J Pain       Date:  2011-09-25       Impact factor: 5.820

Review 3.  The effects of meditation-based interventions on the treatment of fibromyalgia.

Authors:  Elisa H Kozasa; Luiza H Tanaka; Carlos Monson; Stephen Little; Frederico Camelo Leao; Mario P Peres
Journal:  Curr Pain Headache Rep       Date:  2012-10

4.  Perceived injustice in fibromyalgia and rheumatoid arthritis.

Authors:  Robert Ferrari; Anthony Science Russell
Journal:  Clin Rheumatol       Date:  2014-03-04       Impact factor: 2.980

5.  Mindfulness is associated with psychological health and moderates the impact of fibromyalgia.

Authors:  Brandon Pleman; Michelle Park; Xingyi Han; Lori Lyn Price; Raveendhara R Bannuru; William F Harvey; Jeffrey B Driban; Chenchen Wang
Journal:  Clin Rheumatol       Date:  2019-01-14       Impact factor: 2.980

Review 6.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults.

Authors:  R Andrew Moore; Philip J Wiffen; Sheena Derry; Thomas Toelle; Andrew S C Rice
Journal:  Cochrane Database Syst Rev       Date:  2014-04-27

7.  Low-level laser therapy to treat fibromyalgia.

Authors:  J A Ruaro; A R Fréz; M B Ruaro; R A Nicolau
Journal:  Lasers Med Sci       Date:  2014-05-07       Impact factor: 3.161

8.  Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.

Authors:  Jeong Lan Kim; Shilpa Rele; David M Marks; Prakash S Masand; Pallavi Yerramsetty; Robert A Millet; Richard S Keefe; Ashwin A Patkar
Journal:  Prim Care Companion CNS Disord       Date:  2014-12-26

9.  A comparison of the clinical manifestation and pathophysiology of myofascial pain syndrome and fibromyalgia: implications for differential diagnosis and management.

Authors:  Sheryl Bourgaize; Genevieve Newton; Dinesh Kumbhare; John Srbely
Journal:  J Can Chiropr Assoc       Date:  2018-04

10.  Assessing the affective load in the narratives of women suffering from fibromyalgia: the clinicians' appraisal.

Authors:  Christine Cedraschi; Elodie Girard; Valérie Piguet; Jules Desmeules; Anne-Françoise Allaz
Journal:  Health Expect       Date:  2014-12-10       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.